Evidence map›Paper›PMID 24587397›Full record

ArticlePloS one2014

Respiratory syncytial virus infections enhance cigarette smoke induced COPD in mice.

Robert F Foronjy, Abdoulaye J Dabo, Clifford C Taggart, Sinead Weldon, Patrick Geraghty

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 64 citations in OpenAlex.

  1. Trial
  2. Preclinical models of COPD: a state of the art review.The European respiratory journal · 2026
    Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Evaluating Novel Protein Phosphatase 2A Activators as Therapeutics for Emphysema.American journal of respiratory cell and molecular biology · 2023
    Article
  9. Review
  10. Article
  11. Article
  12. Molecular Mechanisms of RSV and Air Pollution Interaction: A Scoping Review.International journal of molecular sciences · 2022
    Article
  13. Review
  14. Review
  15. Review
  16. Sputum Cytokine Profiling in COPD: Comparison Between Stable Disease and Exacerbation.International journal of chronic obstructive pulmonary disease · 2022
    Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Robert F ForonjySt. Luke's Roosevelt Hospital, Mount Sinai Health System, Division of Pulmonary and Critical Care Medicine, New York, New York, United States of America.
Abdoulaye J DaboSt. Luke's Roosevelt Hospital, Mount Sinai Health System, Division of Pulmonary and Critical Care Medicine, New York, New York, United States of America.
Clifford C TaggartCentre for Infection and Immunity, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, Northern Ireland, United Kingdom.
Sinead WeldonCentre for Infection and Immunity, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, Northern Ireland, United Kingdom.
Patrick GeraghtySt. Luke's Roosevelt Hospital, Mount Sinai Health System, Division of Pulmonary and Critical Care Medicine, New York, New York, United States of America.
Mount Sinai Health System · USQueen's University Belfast · GB

Funding

The Effects of PP2A on TNF Signaling and Smoke-Induced Lung InjuryR01HL098528 · NHLBI · ST. LUKE'S-ROOSEVELT INST FOR HLTH SCIS · PI FORONJY, ROBERT F · 2010 to 2014
$2.2M
NHLBI NIH HHS 5R01HL098528-04NHLBI NIH HHS R01 HL098528
6 · The paper itself

Abstract

Respiratory syncytial viral (RSV) infections are a frequent cause of chronic obstructive pulmonary disease (COPD) exacerbations, which are a major factor in disease progression and mortality. RSV is able to evade antiviral defenses to persist in the lungs of COPD patients. Though RSV infection has been identified in COPD, its contribution to cigarette smoke-induced airway inflammation and lung tissue destruction has not been established. Here we examine the long-term effects of cigarette smoke exposure, in combination with monthly RSV infections, on pulmonary inflammation, protease production and remodeling in mice. RSV exposures enhanced the influx of macrophages, neutrophils and lymphocytes to the airways of cigarette smoke exposed C57BL/6J mice. This infiltration of cells was most pronounced around the vasculature and bronchial airways. By itself, RSV caused significant airspace enlargement and fibrosis in mice and these effects were accentuated with concomitant smoke exposure. Combined stimulation with both smoke and RSV synergistically induced cytokine (IL-1α, IL-17, IFN-γ, KC, IL-13, CXCL9, RANTES, MIF and GM-CSF) and protease (MMP-2, -8, -12, -13, -16 and cathepsins E, S, W and Z) expression. In addition, RSV exposure caused marked apoptosis within the airways of infected mice, which was augmented by cigarette smoke exposure. RSV and smoke exposure also reduced protein phosphatase 2A (PP2A) and protein tyrosine phosphates (PTP1B) expression and activity. This is significant as these phosphatases counter smoke-induced inflammation and protease expression. Together, these findings show for the first time that recurrent RSV infection markedly enhances inflammation, apoptosis and tissue destruction in smoke-exposed mice. Indeed, these results indicate that preventing RSV transmission and infection has the potential to significantly impact on COPD severity and progression.

Indexed as

AnimalsApoptosisCathepsinsCell Line, TumorCytokinesGene Expression Regulation, EnzymologicHost-Pathogen InteractionsHumansImmunoblottingLungMice, Inbred C57BLNicotianaPeptide HydrolasesPneumoniaProtein Phosphatase 2Protein Tyrosine Phosphatase, Non-Receptor Type 1cathepsin SCathepsinsCytokinesPeptide HydrolasesProtein Phosphatase 2Protein Tyrosine Phosphatase, Non-Receptor Type 1Ptpn1 protein, mouseSmoke

Identifiers

PMID24587397
PMCPMC3938768
OpenAlexW2002452029

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.